Drug Profile
Alcohol-use disorder and depression therapeutic - Lohocla Research
Alternative Names: NezavistLatest Information Update: 15 Jul 2020
Price :
$50
*
At a glance
- Originator Lohocla Research
- Class Antidepressants; Drug withdrawal therapies
- Mechanism of Action GABA receptor agonists; Glutamate antagonists; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alcoholism; Depressive disorders
Most Recent Events
- 15 Jul 2020 Preclinical trials in Alcoholism in USA (unspecified route) (Lohocla Research pipeline, July 2020)
- 15 Jul 2020 Preclinical trials in Depressive disorders in USA (unspecified route) (Lohocla Research pipeline, July 2020)
- 15 Jul 2020 Lohocla Research expects an Investigational New Drug (IND) approval of Nezavist® from the US FDA (Lohocla Research pipeline, July 2020)